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Brain MRIAbstract Aim of the study: To evaluate the role of MRI in the detection of the side effects of
chemotherapy on the brain in leukemic children presenting with clinical symptoms.
Patients and methods: 20 pediatric patients aged between 1 and 16 years receiving or have received
chemotherapy for acute leukemia have undergone MR examination of the brain for evaluation of
neurological symptoms related to treatment from August to December 2015. Written consent was
taken from the patients.
Results: This study included 20 children, 15 (75%) were males and 5 (25%) were females. Their
ages at the time of the study ranged from 1 to 16 years. 17 patients (85%) were on maintenance
chemotherapy, 2 patients (10%) were on induction and 1 patient (5%) had finished treatment. Mul-
tiple complications were recorded by MRI and its correlation to the treatment phase of the cases.
All cases of Sino-venous thrombosis and hemorrhage occurred within the maintenance phase.
Leukoencephalopathy was divided equally between maintenance and induction phases. Brain atro-
phy was divided equally between induction and maintenance phases. PRES occurred within the
maintenance phase. Most of infection cases (sinusitis and otitis media) occurred within mainte-
nance; only one case was seen in a patient who just ended his chemotherapy.
Conclusion: Chemotherapy is associated with certain side effects that can be evaluated by utilization
ofMRI. An elevated degree of suspicion is needed to recognize the radiological features of CNS com-
plications of chemotherapy and familiarity with the imaging findings is essential for proper diagnosis
and further treatment of neurological symptoms in pediatric patients with leukemia.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Table 1 Phase of chemotherapy at study time.
Phase No. %
Induction 2 10
Intensification 0 0
Maintenance 17 85
Finished 1 5
Table 2 MR findings among the studied groups.
Finding No %
PRES 1 5
Sino-venous thrombosis 6 30
Hemorrhage 2 10
Leukoencephalopathy 2 10
Brain atrophy 2 10
Sinusitis 6 30
Middle ear infection 1 5
Fig. 2 MR Findings among the studied group.
Fig. 3 Frequency of the MRI diagnoses within the phases of
chemotherapy.
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Leukemia is the most common malignancy in children. Acute
lymphoblastic leukemia accounts for one-fourth of all child-
hood cancers and approximately 75% of all childhood leuke-
mia. The peak of it occurs between 2 and 5 years (1).
The etiology of leukemia is unknown, but some factors pre-
dispose to it as ionizing radiation, chemicals, and drugs.
Genetic factors also may predispose to it as increased incidence
in siblings of leukemia, trisomy 21, Fanconi anemia, congeni-
tal Agammaglobulinemia, and neurofibromatosis (2).
Diagnosis depends on blood count which shows blast cells,
that is confirmed by bone marrow aspiration containing more
than 55 blasts/mm3 (3).
Modern treatment protocols have dramatically improved
the prognosis. Therapeutic approaches consist of multimodal
chemotherapy and radiotherapy. Prognostic factors include
age, sex, race, nutritional status, the immunologic subtype,
platelet count, rapidity of cytoreduction, and the presence of
organomegaly or lymphadenopathy (3).
As advances in cancer therapy improve the prognosis of
patients with childhood malignancies, awareness of the conse-
quences of treatment methods assumes increasing importance
(4).
Some types of chemotherapy can leave young patients with
short-term or long-term neurological side effects. Methotrex-
ate can cause neurotoxicity and cognition impairment within
3 days of administration (5).
Up to 2% of patients treated with l-asparaginase develop
hemorrhagic or nonhemorrhagic infarcts, usually secondary
to sinovenous occlusion (6).
Agents, particularly methotrexate, cisplatin, arabinosylcy-
tosine, carmustine, and thiotepa, occasionally cause cerebral
white matter anomalies (7).
Central nervous system prophylactic treatment as well as
other disease complications may produce many abnormalitiesInduction Intensification Maintenance Finished 
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Fig. 1 Phase of chemotherapy at study time.seen on the cranial MRI. Cortical atrophy, ventricular dilata-
tion and white matter hyperintensities are documented (8).
Both the underlying malignancy and the anti-neoplastic
therapy can cause immunosuppression, leading to infection.
Fungi are the most frequent causal microorganisms and typi-
cally affect patients having absolute granulocytic counts of less
than 100/mm3 for more than 2 weeks (9).
MRI is known for its superior soft tissue imaging. The use
of MRI in the early detection of chemotherapy side effects on
pediatrics brain prompts early management and avoidance or
at least minimizing long term side effects (10).
The aim of this prospective study was to evaluate the role of
MRI in the detection of the side effects of chemotherapy on
the brain in leukemic children presenting with clinically related
symptoms.
Table 3 Frequency of the MRI diagnoses within the phases of
chemotherapy.
MRI abnormality Phase of chemo.
Induction Maintenance Finished
PRES 1
Hemorrhage 2
Sinovenous thrombosis 6
Leukoencephalopathy 1 1
Brain atrophy 1 1
Otitis media 1
Sinusitis 5 1
a
T1
c
FLAIR
ADC
Fig. 4 (a, b, c, d & e): case (1). Case 1: 4-year-old female, with acute
on maintenance chemotherapy presented with hemiplegia and recurren
abnormalities. Bilateral diffuse cerebral areas of abnormal MR signal
right side eliciting high T2 and FLAIR WIs SI (b) and (c) (arrows). DW
lobe (arrows). Diagnosis: posterior reversible encephalopathy syndrom
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2.1. Patients
Twenty children had undergone MR imaging, and they were
sent from the pediatric oncology department and the intensive
care to the radiology department from August to December
2015. Written consent was taken from patients.
Essential inclusion criteria included the following:
1. Pediatricians age 1–16 years.
2. Confirmed case of leukemia.b
T2
d
DWI (b 800)
e
lymphoblastic leukemia, started chemotherapy one year ago, now
t fits. MRI (a, b, c & e) was done .T1 WI (a) shows no significant
involving cortical, sub-cortical and deep white matter more on the
I (d) and ADC (e) show area of restricted diffusion at the occipital
e (PRES).
a b
T1 T2
c d
FLAIR DWI (b0)
e f g
DWI b 1000 ADC MRV
Fig. 5 (a, b, c, d, e, f & g): Case (2). Case 2: 9-year-old patient with ALL, on maintenance chemotherapy and enoxaparin for previous
thrombotic event. MRI was done (a, b, c, d, e, f & g) T1 WI (a) shows right temporal lobe cortical (opercula) area of high T1 signal
(arrow). T2 WI (b) and FLAIR (c) show right temporal lobe and supra-tentorial white matter high signal intensity with hypointense rim of
hemosiderin (arrows). DWI (b0 & 1000) (d) and (e) and ADC (f) show foci of restricted diffusion at the right temporal lobe (arrows)
representing areas of hemorrhage and infarction. MRV (g) shows attenuated right transverse and sigmoid sinuses (arrows). Diagnosis:
Hemorrhagic ischemic insult secondary to venous impairment and Supra-tentorial leukoencephalopathy.
1068 N.M. Khalifa et al.3. Leukemia patients ended or under chemotherapy with pos-
itive neurological symptoms.Exclusion criteria included those who receive radiotherapy or
combined radio and chemotherapy, and patients with leukemic
infiltrates.
The study includes 15 males and 5 females.
2.2. Magnetic resonance imaging
The MRI examinations were performed to all the cases.
They were done on a 1.5 tesla super conducting system(Phillips MRI machine) using an extremity coil of the appro-
priate size.
Pre-imaging preparation:
1. Fasting for 4 h.
2. Cannula: 24G or 22G.
3. Sedation was performed with oral 10% chloral hydrate
(50–75 mg/kg) under supervision of an experienced pedia-
trician for irritable patients; otherwise, they were not
sedated.
a b c
T1               T2 T2
d
DWI (b 1000 )
e f
Gradient echo MRV
Fig. 6 (a, b, c, d, e & f): Case (3). Case 3: Male patient 4-year-old with ALL, on maintenance chemotherapy, presented with persistent
headache. MRI was done (a, b, c, d, e & f) T1 & T2 WIs (a, b & c) show left cerebellar hemisphere area of high signal intensity and
scattered foci of high signal intensity are seen at the centrum semi-ovale and left frontal subcortical region (arrows). DWI b1000 (d) Shows
left cerebellar hemisphere area of restricted diffusion (reduced ADC) (arrow). Gradient echo WIs (d) shows left cerebellar area of low SI
and high SI at its lateral aspect (arrow). MRV (e) shows attenuated anterior aspect of superior sagittal and left transverse sinuses (arrows).
Diagnosis: Left cerebellar hemorrhagic infarction secondary to venous impairment and white matter acute ischemic foci.
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1. T1 weighted spin-echo images and its value (TR = 400-
500 ms, TE = 15–20 ms, FOV= 200 mm, acquisition
matrix = 256  141 pixels, slice thickness = 4 mm, with
0.5 mm gap). Axial and sagittal T1 weighted images pre &
post contrast administration for depicting parenchymal vol-
ume, ischemia, hemorrhage and focal lesions features that
may have important diagnostic and prognostic implications.
2. T2 weighted spin-echo images and its value (TR = 3500–
5000 ms, TE = 100–120 ms, FOV= 200 mm, acquisition
matrix = 512  301 pixel, slice thickness = 4 mm, with
0.5 mm gap). Axial and sagittal T2-weighted MR image
provides good contrast between gray and white matter,
allowing identification of any white matter signal intensity
abnormalities.
3. Axial fluid attenuated inversion recovery (FLAIR) images
(TR = 11000 ms, TE = 140 ms, inversion time = 2800 ms,
FOV= 200 mm, acquisition matrix = 256  137 pixels,
slice thickness = 4 mm, with 0.5 mm gap).4. Axial diffusion weighted images and its value
(TR = 3160 ms, TE = 100 ms, FOV= 200 mm, acquisi-
tion matrix = 256  77 pixels, slice thickness = 4 mm,
with 0.5 mm gap). The high water content in the extra-
cellular space and rapid water molecular diffusion affect
the appearance of the brain on diffusion-weighted
image.
5. MRV: Time-of-flight MR venography was performed in
patients with cerebrovascular disorders. The parameters
used with this technique were as follows: 30/9/1: field of
view, 22–25 cm; matrix, 219  250; flip angle, 50; section
thickness, 3 mm; section slab thickness, 3–7.5.
Interpretation of MRI findings:
1. Assessment of the brain volume and Ventricular system.
2. Reporting intra- or extra-axial hemorrhage.
3. Assessment of the white matter for signal changes.
4. Assessment of cerebral venous sinuses.
5. Monitoring of complications as intracranial infections.
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This prospective study included 20 children, 15 (75%) were
males and 5 (25%) were females. All of them were confirmed
cases of acute leukemia receiving chemotherapy at different
phases. Their ages at the time of the study ranged from 1 to
16 years.
19 patients (95%) had acute lymphoblastic leukemia
(ALL), and only 1 patient (5%) had acute myeloid leukemia.
17 patients (85%) were on maintenance chemotherapy, 2
patients (10%) were on induction and 1 patient (5%) had fin-
ished treatment (Table 1 and Fig. 1).
According to the clinical presentation MRI was performed
to our 20 patients and the following conditions were diagnosed
from the obtained MR images:
1. 1 patient (5%) developed Posterior reversible encephalopa-
thy syndrome (PRES).
2. 6 patients (30%) developed Sino-venous thrombosis.
3. 2 patients (10%) developed intra-cerebral hemorrhage.
4. 2 patients (10%) developed white matter changes
(Leukoencephalopathy).
5. 7 patients (35%) developed infection:
 6 patients (30%) had sinusitis.
 1 patient (5%) had middle ear infection.
6. 2 patients (10%) developed brain atrophy (Table 2 and
Fig. 2).a
T2
c d
FLAIR                 DWI
Fig. 7 (a, b, c, d & e): Case (4). Case 4: Male patient, 6-year-old, with
(a, b, c, d & e) revealed: T2 WIs show bilateral maxillary and ethmoi
globe of hemorrhagic changes and faint abnormal high signal in peri
abnormal diffusion signal in periventricular white matter (FLAIR is mo
maxillary and ethmoidal sinusitis and right globe of hemorrhagic chaThe frequency by which each MRI diagnosis was seen at
each phase of chemotherapy is depicted in the following
Table 3 and Fig. 3.
In Table 3 and Fig. 3 we can see that:
1. all cases of Sino-venous thrombosis and hemorrhage
occurred within the maintenance phase,
2. leukoencephalopathy was divided equally between mainte-
nance and induction phases,
3. brain atrophy was divided equally between induction and
maintenance phases,
4. PRES occurred within the maintenance phase, and
5. most of infection cases (sinusitis and otitis media) occurred
within maintenance, and only one case was seen in a patient
who had just ended his chemotherapy.
4. Discussion
Leukemia is the most common type of cancer in children. The
majority of childhood leukemia is of the ALL type which is
responsible for about 1,400 deaths a year in the U.S., and it
can progress quickly if untreated. However, ALL is one of
the most curable cancers and survival rates are now high.
Despite contemporary treatment approaches which favor
the use of chemotherapy (including intrathecal therapy) over
radiotherapy in the treatment of CNS leukemia, children still
occasionally experience morbid neurotoxicity.b
FLAIR
e
(b 800) ADC
ALL, MRI was done as routine at week 48 of chemotherapy. MRI
dal sinusitis. FLAIR (b & c) abnormal FLAIR signal in the right
ventricular white matter (arrow). DWI (d) and ADC (e) show no
re sensitive). Diagnosis: Post therapeutic encephalopathy, bilateral
nges.
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neurotoxic sequelae in children, and often suggest specific eti-
ologies. Specific neuroimaging findings frequently indicate a
need to alter anti-leukemia therapy (11).
According to the clinical presentation MRI was performed
on our 20 patients and the following conditions were diag-
nosed from the obtained MR images: 1 patient (5%) developed
Posterior reversible encephalopathy syndrome (PRES), 6
patients (30%) developed Sino-venous thrombosis, 2 patients
(10%) developed intra-cerebral hemorrhage, 2 patients (10%)
developed white matter changes (leukoencephalopathy), 7
patients (35%) developed infection, 6 patients (30%) had
sinusitis, 1 patient (5%) had middle ear infection and 2
patients (10%) developed brain atrophy (see cases 1–6)
(Figs. 4–9).
In a recent retrospective study carried out by Roula et al.
(12) data were obtained from chart review of 196 pediatric
patients with ALL treated between January 2002 and July
2012, 94 patients had neuroimaging studies of those, 60 were
normal and 34 (36.1%) patients had abnormalities. The most
encountered findings in their study were brain atrophy
(n= 11 patients) and dural venous thrombosis (n= 10). Theira
T2
c
MRV
Fig. 8 (a,b,c): Case (5). Case 5: Male patient 7-year-old, Down sy
relapse during maintenance chemotherapy. C/O: severe headache. M
cisterns and deep cortical sulci and early bi-temporal CSF hygrom
thrombosis, mainly anterior 2/3 with attempted partial recanalization o
and atrophic changes of the brain.diagnosis was based on radiological features with or without
tissue confirmation based on the clinical presentation. They
concluded that CNS complications are common in ALL dur-
ing therapy and require prompt diagnosis and timely interven-
tion for better outcome and can provide essential information
for delineating priorities for neuroimaging in the detection of
CNS complications (12).
In a study done by Katsimpardi et al. (13) infectious com-
plications were the most common involving (35%) of patients,
which match our study (35%). Most cases {85.7% (6 out of 7
patients)} occurred during maintenance while {14.3% (1 out of
7 patients)} had ended chemotherapy. 85.7% of our patients
had sinusitis, the remaining patient had otitis media, and none
of our patients had brain tissue infection which in a study done
by Kishikawa et al. (14) accounted for 18% of patients with
CNS symptoms.
In our study dural venous thrombosis came as second most
common complication at 30% after infections. Most com-
monly involved location was superior sagittal sinus (83.3%)
followed by the transverse and sigmoid sinuses together
(16.7%). Other venous sinus involvements were not encoun-
tered in our study. 83.3% of sinus thromboses occurred inb
T2
 
ndrome, ALL, patient shifted to second line chemotherapy after
R revealed: T2WI (a & b) ventriculomegaly with widened CSF
as are noted (arrows). MRV (c) shows superior sagittal sinus
f its posterior 1/3 (arrows). Diagnosis: Thrombotic process of SSS
a b
T2 FLAIR
c
T2
Fig. 9 (a,b,c): Case (6). Case 6: Male patient-4 year-old, ALL, on maintenance chemotherapy, MRI was done as routine at week 48 of
chemotherapy. MR revealed: T2 WIs and FLAIR (a & b) show subtle bilateral symmetrical high signal in occipital periventricular white
matter (arrows). Bilateral maxillary sinusitis (c). Diagnosis: Subtle element of supra-tentorial leukoencephalopathy, and bilateral
maxillary sinusitis.
1072 N.M. Khalifa et al.ALL patients and 16.7% occurred with AML and all the cases
were encountered during the maintenance phase of chemother-
apy. In a study done by Athale et al. (15) the risk of thrombo-
sis is increased in ALL patients. Its frequency ranges between
1.1% and 36.7%, a quite large variation related to several fac-
tors, such as different definitions of thrombosis (symptomatic
vs. asymptomatic), diagnostic methods for its detection, study
design (prospective vs. retrospective), and differences in treat-
ment protocols. CT scan with contrast misses the diagnosis of
dural sinus thrombosis in up to 40% of patients. MRI is more
sensitive for detection of early infarction. Post-contrast MRI
and MR venography identify dural sinus thrombus when only
subtle infarction is visible on plain CT. CT venography or
MRI with venous MRV is now the methods of choice for
investigation. The diagnosis is established by demonstrating
a lack of flow in the dural sinuses and cerebral veins, with or
without typical images of brain infarcts. Parenchymal MR
and MRV are important in the demonstration of both the
infarct and the thrombus within the sinuses. On MRI, the
thrombus is readily recognizable in the sub-acute phase, when
it is of high signal intensity on T1-weighted images; MRV is
then often not required. In the acute phase, the thrombus
shows iso-intense signal intensity on T1-weighted and low sig-nal on T2-weighted imaging. This can be mistaken for flowing
blood but MRV will demonstrate an absence of flow in the
thrombosed sinus (16).
In our study equal percentage of patients developed hemor-
rhagic complication, leukoencephalopathy & brain atrophy
each presenting (10%). In a study done by Chamberlain (17)
hemorrhagic complications were common in patients with
acute leukemia (approximately 20%) which doubles our result;
this may be attributed to the small number of cases in our
study. Other studies showed that hemorrhage is seen in 2.7%
in ALL kids, Laningham et al. (11), 6% in AML, 18.4% in
APL (acute promyelocytic leukemia) and 5% in non-APL,
Chen et al. (18), shows that the type of leukemia also affects
the risk of hemorrhage.
In a study done by Barkovich et al. (19), leukoencephalopa-
thy was seen in 10% of patients treated with intrathecal
methotrexate which matches our result. In our study leukoen-
cephalopathy cases were seen in maintenance in induction
phases equally. In a study by Laningham et al. (11) 16% were
seen at the beginning of consolidation therapy, 60% at the
beginning of maintenance therapy, 76% after all courses,
and 52% at 1 year after diagnosis, and our study covered a
short time period to show such results.
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atrophy was observed in 74% and 65% of the CT examina-
tions performed during and after cessation of treatment,
respectively. The highest incidence of brain atrophy (78%)
occurred during the administration of intrathecal chemother-
apy. All children younger than 2 years exhibited brain atrophy.
In our study only 10% of the patients showed this consequence
which is big difference that could be attributed to the small
sample size in our study.
In our study PRES came as the least encountered complica-
tion involving 5% of the patients phase. Case reports of
approximately 40 children treated for ALL are discussed in
the literature (21). In our study PRES occurred during the
maintenance phase of ALL treatment. This does not corre-
spond to other reports of PRES (22–26) which all report PRES
during the induction phase. Because of the administration of
multiple drugs in a short time it is difficult to identify the drug
potentially responsible for PRES.
We conclude that MRI is a valuable modality in early
detection of CNS complication in leukemia patients under
chemotherapy. It acts as a helpful guide for clinicians to regu-
late anti-leukemia therapy.
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